Global nanotech drug delivery expected to soar to $136B by 2021; Industry, academics link on biodegradable regenerative stent;

> The global market for nanotechnology-enabled drug delivery therapeutics will grow from $2.3 billion today to $136 billion by 2021, according to a new report from market analyst firm ResearchMoz. Release

> Revenue from Becton Dickinson's ($BDX) Medical division, which sells drug delivery systems, diabetes care and disposable products, jumped 2.6% to $950 million in the fiscal first quarter that ended Dec. 31, Reuters reports. Story

> Dutch specialty pharmaceutical company OctoPlus will work with Ferring Pharmaceuticals to develop an undisclosed compound. OctoPlus is known, in part, for supplying drug delivery tech to develop controlled-release versions of both existing and new drugs. Release

> QualiMed Innovative Medizinprodukte of Hamburg, Germany, along with Yale University, University College of London and others will work on developing a functioning biodegradable regenerative stent. Release

> Kedem Pharmaceuticals will profile its sublingual (under the tongue) drug delivery technology at the World Money Show in Orlando, FL, Feb. 9-12, and present an update on X-Excite, its lead drug for erectile dysfunction. Release

> Generic drug maker Mylan ($MYL) has acquired manufacturing and marketing rights to two skin drugs from Valeant Pharmaceuticals ($VRX). One is a generic acne gel treatment; the other is a drug cream for basal cell carcinomas and actinic or solar keratosis, according to Drugstorenews.com. Story

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.